Advances in cancer therapy have been substantial in terms of molecular understanding of disease mechanisms, however these advances have not translated into increased survival in the majority of cancer types. One unsolved problem in current cancer therapeutics is the substantial immune suppression seen in patients. Conventionally, investigations in this area have focused on antigen-nonspecific immune suppressive molecules such as cytokines and T cell apoptosis inducing molecules such as Fas ligand. More recently, studies have demonstrated nanovesicle particles termed exosomes are involved not only in stimulation but also inhibition of immunity in physiological conditions. Interestingly, exosomes secreted by cancer cells have been demonstrated to express tumor antigens, as well as immune suppressive molecules such as PD-1L and FasL. Concentrations of exosomes from plasma of cancer patients have been associated with spontaneous T cell apoptosis, which is associated in some situations with shortened survival. In this paper we place the “exosome-immune suppression” concept in perspective of other tumor immune evasion mechanisms. We conclude by discussing a novel therapeutic approach to cancer immune suppression by extracorporeal removal of exosomes using hollow fiber filtration technology.
The Stem Cell Institute has integrated Intranasal MTF Therapy into its autism protocol:
MTF therapy features exosomes and over 300 beneficial molecules
Works in synergy with our stem cells
Offers anti-inflammatory and regenerative effects
Delivered in an easy-to-administer aerosol format via the nose
To discover more about MTF and its benefits, click here
We use cookies to ensure that we give you the best experience on our website. To find out more about cookies and how we use them on this site, see our privacy policy.AcceptPrivacy Policy